Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease
Open Access
- 18 August 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (1) , 56-67
Abstract
The aim of this article was to compare rates of all-cause death at 10 years following coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in patients with or without diabetes. The SYNTAXES study evaluated up to 10-year survival of 1800 patients with three-vessel disease (3VD) and/or left main coronary artery disease (LMCAD) randomized to receive either PCI or CABG in the SYNTAX trial. Ten-year all-cause death according to diabetic status and revascularization strategy was examined. In diabetics (n = 452), the risk of mortality was numerically higher with PCI compared with CABG at 5 years [19.6% vs. 13.3%, hazard ratio (HR): 1.53, 95% confidence interval (CI): 0.96, 2.43, P = 0.075], with the opposite seen between 5 and 10 years (PCI vs. CABG: 20.8% vs. 24.4%, HR: 0.82, 95% CI: 0.52, 1.27, P = 0.366). Irrespective of diabetic status, there was no significant difference in all-cause death at 10 years between patients receiving PCI or CABG, the absolute treatment difference was 1.9% in diabetics (PCI vs. CABG: 36.4% vs. 34.5%, difference: 1.9%, 95% CI: −7.6%, 11.1%, P = 0.551). Among insulin-treated patients (n = 182), all-cause death at 10 years was numerically higher with PCI (47.9% vs. 39.6%, difference: 8.2%, 95% CI: −6.5%, 22.5%, P = 0.227). The treatment effects of PCI vs. CABG on all-cause death at 10 years in patients with 3VD and/or LMCAD were similar irrespective of the presence of diabetes. There may, however, be a survival benefit with CABG in patients with insulin-treated diabetes. The association between revascularization strategy and very long-term ischaemic and safety outcomes for patients with diabetes needs further investigation in dedicated trials. SYNTAX: ClinicalTrials.gov reference: NCT00114972 and SYNTAX Extended Survival: ClinicalTrials.gov reference: NCT03417050. The treatment effects of PCI versus CABG on all-cause death at 10 years in 3VD/LMCAD patients with pharmacologically treated diabetes and insulin-treated diabetes.Keywords
Funding Information
- German Foundation of Heart Research
- Science Foundation Research Professorship Award (15/RP/2765)
This publication has 48 references indexed in Scilit:
- Effectiveness of Percutaneous Coronary Intervention With Drug‐Eluting Stents Compared With Bypass Surgery in Diabetics With Multivessel Coronary Disease: Comprehensive Systematic Review and Meta‐analysis of Randomized Clinical DataJournal of the American Heart Association, 2013
- Strategies for Multivessel Revascularization in Patients with DiabetesNew England Journal of Medicine, 2012
- Quantification and Impact of Untreated Coronary Artery Disease After Percutaneous Coronary InterventionJACC, 2012
- Current concepts on coronary revascularization in diabetic patientsEuropean Heart Journal, 2011
- Randomized Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Diabetic PatientsJACC, 2010
- Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery DiseaseNew England Journal of Medicine, 2009
- The Final 10-Year Follow-Up Results From the BARI Randomized TrialJACC, 2007
- The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: Design, rationale, and run-in phaseAmerican Heart Journal, 2006
- Impact of Completeness of Percutaneous Coronary Intervention Revascularization on Long-Term Outcomes in the Stent EraCirculation, 2006
- Cause of death in clinical researchJACC, 1999